Initial results from CDNF clinical trial announced
Herantis Pharma has published initial results from a phase 1/2 study of an experimental protective protein called CDNF which may hold potential to slow, stop or reverse Parkinson's.
GDNF: where are we 1 year on?
GDNF clinical trial results in 2019 revealed signs that GDNF may make it possible to repair the cells damaged in people with Parkinson’s. We take a look at where we are 1 year later.
BT13 molecule offers hope for halting Parkinson’s
A promising molecule, called BT13, has offered hope for a new treatment that could stop or slow Parkinson’s, something no treatment can currently do.
Gut bacteria could guard against Parkinson’s
New research suggests that a bacteria which boosts digestive health can slow – and even reverse – the build-up of a protein associated with Parkinson’s.
Poll finds a quarter of people with Parkinson’s are wrongly diagnosed
In our survey of more than 2,000 people, more than a quarter (26%) reported they were misdiagnosed with a different condition before receiving the correct Parkinson’s diagnosis.
Full results of repurposed cancer drug trial highlight potential benefits
Previous top line results indicated that, while safe, Nilotinib failed to show benefit. The full results now show that there may be some potential benefits.
8 remarkable things we achieved together in 2019, and recent years
2019 was another exciting year of progress. Here are 8 of the highlights, and 8 ways you can still get involved.
New international initiative to investigate the genetics of Parkinson’s
As part of the Aligning Science Across Parkinson’s (ASAP) initiative, an ambitious global five-year programme was announced today to understand the genetic root of Parkinson’s.
Results of phase 2 nilotinib study show no benefit
Results have been shared from the US-based phase 2 clinical trial of nilotinib in people with moderate to advanced Parkinson's.
While safe and tolerable, the repurposed drug did not appear to have beneficial effects.